Skip to main content

Table 1 Demographic data

From: Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy

Patient demographics (n = 112)
Age (years), mean (range)68(48–78)
PSA (ng/mL), mean (range)34.5(1.7–276)
 median21 
Gleason
 7 (3 + 4), n17(15.2%)
 7 (4 + 3), n24(21.4%)
 8, n10(8.9%)
 9, n61(54.5%)
T-stage
 T1, n24(21.4%)
 T2, n37(33.0%)
 T3, n47(42.0%)
 T4, n4(3.6%)
EAU risk score
 Favorable* intermediate, n7(6.3%)
 Unfavorable intermediate risk, n6(5.4%)
 High risk, n99(88.4%)
Reason for PSMA-PET/CT
 CT equivocal30(26.8%)
 Bone scan equivocal22(19.6%)
 Very high risk and no metastases according to BS or CT28(25.0%)
 Participation in a PSMA-study20(17.9%)
 Miscellaneous12(10.7%)
Bone scintigraphy prior to inclusion
 Planar whole body23(20.5%)
 Planar whole body + SPECT/CT89(79.5%)
Time between PSMA-PET/CT and BS (days)
 Median (range)22(6–80)
  1. BS bone scintigraphy, CT computed tomography, EAU European Association of Urology, SPECT single-photon emission computed tomography
  2. *Intermediate EAU risk differentiate between patients with Gleason 7 (3+4) as favorable and Gleason 7 (4 + 3) as unfavorable